Drug development is a high-risk, high-reward endeavor, often compared to a lottery with a low chance of a massive payout. To mitigate this inherent risk, financial engineering strategies have been developed to make the process more sustainable. One key approach, pioneered by Andrew Lo, involves bundling numerous drug programs into a single entity to diversify risk and ensure that a successful drug can cover the failures of others. This strategy aims to make the high-stakes game of drug discovery more palatable for investors and researchers alike. AI
Summary written by gemini-2.5-flash-lite from 1 source. How we write summaries →
RANK_REASON The item is an opinion piece discussing financial strategies in biotech, referencing a professor and a nature paper, but not announcing a new model or product.
